Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Core Insights - Medicus Pharma Ltd. has initiated patient recruitment for the SKNJCT-004 phase 2 clinical study aimed at non-invasively treating basal cell carcinoma (BCC) of the skin [1] Company Summary - Medicus Pharma Ltd. is a biotech/life sciences company focused on advancing clinical development programs for novel and potentially disruptive therapeutic assets [1] Industry Context - The study is being conducted at Cleveland Clinic Abu Dhabi (CCAD), indicating a collaboration between the company and a prominent healthcare institution [1]